$1.88
-0.20 (-9.62%)
Open$1.98
Previous Close$2.08
Day High$2.02
Day Low$1.79
52W High$20.32
52W Low$0.72
Volume—
Avg Volume43.0K
Market Cap29.05M
P/E Ratio—
EPS$-1.69
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+1,503.2% upside
Current
$1.88
$1.88
Target
$30.14
$30.14
$22.58
$30.14 avg
$41.69
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 2.48M | 2.49M | 2.71M |
| Net Income | -380,025 | -467,867 | -467,071 |
| Profit Margin | -15.3% | -18.8% | -17.2% |
| EBITDA | -552,767 | -558,041 | -685,415 |
| Free Cash Flow | -221,579 | -328,689 | -323,480 |
| Rev Growth | +22.9% | +23.1% | -7.6% |
| Debt/Equity | 0.29 | 0.26 | 0.28 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |